Dare Bioscience (NASDAQ:DARE) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?

Shares of Dare Bioscience, Inc. (NASDAQ:DARE) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.10 and traded as low as $1.85. Dare Bioscience shares last traded at $1.95, with a volume of 78,714 shares.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dare Bioscience in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Dare Bioscience in a research report on Tuesday, December 2nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $10.00.

Dare Bioscience Stock Down 1.0%

The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.18 and a current ratio of 1.18. The company has a market capitalization of $27.87 million, a PE ratio of -1.04 and a beta of 0.78. The firm’s 50-day simple moving average is $1.96 and its 200 day simple moving average is $2.10.

Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Thursday, November 13th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.01 million. As a group, equities research analysts forecast that Dare Bioscience, Inc. will post -0.49 earnings per share for the current year.

Hedge Funds Weigh In On Dare Bioscience

A number of hedge funds have recently bought and sold shares of DARE. AMH Equity Ltd boosted its stake in shares of Dare Bioscience by 20.0% during the 3rd quarter. AMH Equity Ltd now owns 232,373 shares of the biotechnology company’s stock worth $488,000 after acquiring an additional 38,770 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Dare Bioscience in the third quarter worth $37,000. Finally, Raymond James Financial Inc. boosted its position in Dare Bioscience by 810.6% during the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 13,650 shares during the last quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.